Researchers from MIT and Harvard have identified the optical features within a limpet’s shell that allow the mollusk to display blue stripes, reports Nidhi Subbaraman for BetaBoston. The findings could inspire developments in augmented reality screens.
Sarah Hedgecock writes for Forbes about how researchers have made major advances in mapping the human epigenome. Prof. Manolis Kellis explains that the new findings allow researchers to “ go from a static picture of the genome, which is effectively the book of life, to a dynamic picture of a genome.”
A team of researchers has published a map of the human epigenome, which could be useful in better understanding how to treat disease, writes Amanda Schupak for CBS News. Prof. Manolis Kellis explains that the findings provide “a reference for studying the molecular basis of human disease, by revealing the control regions that harbor genetic variants associated with different disorders."
Marcus Woo writes for Wired about how researchers have published a number of articles providing new information on the human epigenome, which controls which genes get switched on or off. “It is giving us a view of the living, breathing genome in motion, as opposed to a static picture of DNA,” explains Prof. Manolis Kellis.
Rachel Feltman of The Washington Post reports that a team led by Professor Manolis Kellis has released the most complete map of the human epigenome to date. “The researchers tied specific cell changes to 58 different biological traits,” writes Feltman. “Sometimes the epigenomic changes of a cell reveal possible clues about disease.”
Work on mapping the human epigenome, led by Professor Manolis Kellis, could reveal the origins of diseases such as cancer and Alzheimer’s, reports Carolyn Johnson for The Boston Globe. “The research was one major piece of a $240 million National Institutes of Health program that funded 88 grants over 10 years,” Johnson explains.
For the first time, researchers have mapped the epigenome, identifying the switches that can turn individual genes on or off, reports Sharon Beagley for Reuters. Says Prof. Manolis Kellis of the need to understand the epigenome, "The only way you can deliver on the promise of precision medicine is by including the epigenome.”
Researchers have mapped the epigenome, shedding light on how genes are controlled, which could be useful in understanding disease, reports Gina Kolata for The New York Times. “We now have an unprecedented view of the living human genome,” says Prof. Manolis Kellis.
Kevin Hartnett of The Boston Globe looks at Professor Christine Ortiz’s work to develop better body armor technology by mimicking the tough qualities of fish scales. “Armored fish have multi-hit capability,” explains Ortiz. “Basically, when it gets hit, it just cracks locally in a circle.”
In an article for Science, Jocelyn Kaiser writes about how Prof. Robert Weinberg’s company, Verastem Inc., is starting a new round of clinical trials to test the theory that by targeting cancer stem cells, the disease can be controlled.
Financial Times reporter John Authers highlights Prof. Andrew Lo’s work examining how human aversion to risk impacts financial decisions. Lo’s research provides evidence that “investors in markets will take risk-averse actions rather than the purely rational decisions that economists have classically assumed."
MIT alumnus Noam Angrist and seniors Anisha Gururaj and Elliot H. Akama-Garren were among 32 Rhodes scholars selected from the U.S. this year, reports Jennifer Smith for The Boston Globe. “The American scholars will join an international group of students chosen from 14 other global jurisdictions, according to the Rhodes Trust,” Smith reports.
Two MIT seniors and alumnus Noam Angrist have been named Rhodes Scholars, reports Dave Collins for the Associated Press. “It’s a total dream come true,” says Angrist. “The skills I will get at (Oxford) are just incredible, and I’ll come back into the world fully equipped to do what I love to do.”
Philip Ball of The Guardian speaks with graduate student Steve Ramirez about the potential for neuroscientist to one day be able to replace bad memories with good ones. “I see a world where we can reactivate any kind of memory we like, or erase unwanted memories,” says Ramirez.
Richard Knox writes for WBUR about Grace Silva, a cancer patient whose tumor was analyzed by a team from MIT and Harvard. The team uncovered genetic mutations in her tumor that allowed them to treat her with a drug matched precisely to her condition, a model for how cancer researchers hope to eventually treat all patients.